NCT05083260 - NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2022

Primary Completion Date

November 21, 2022

Study Completion Date

January 4, 2023

Conditions

Parkinson Disease

Interventions

DRUG

NE3107

NE3107 is an investigational orally bioavailable, blood-brain barrier permeable anti-inflammatory agent with a new mechanism of action targeting multiple mechanisms of pathology in Parkinson's disease

DRUG

placebo

Hard gelatin capsule containing only common excipients for oral formulations

Trial Locations (16)

10003

New York Neurology Associates, New York

27612

M3 Wake Research, Raleigh

27705

Duke University, Durham

32159

Charter Research, Lady Lake

32792

Charter Research, Winter Park

33009

Velocity, Hallandale

33122

Premier Clinical Research Institute, Miami

33172

First Excellent Research Group, Miami

First Excellent Research, Miami

33175

EZY Medical Research, Miami

33486

Parkinson's Disease & Movement Disorders Center Of Boca Raton, Boca Raton

43614

University of Toledo, Toledo

48334

Quest Research Institute, Farmington Hills

75092

Texas Institute for Neurological Disorders, Sherman

80113

Rocky Mountain Movement Disorders Center, Englewood

99202

Inland Northwest Research, Spokane